8 rezultati
The goal of this study is to establish the effect of the compensation of vitamin D deficiency in the treatment of drug-resistant epilepsy with a high level of evidence in a large population. For that, the investigator aim to perform a controlled multicentre prospective double-blind randomized study
The goal of the present open label study is to obtain pilot data to evaluate the efficacy and safety of KD in adults with intractable epilepsy. Investigators will evaluate the effect of KD on seizure frequency and on adverse events. Investigators will also evaluate serum levels of the ketone body,
I Purpose: The purpose of this multi-centre study is to further assess the safety and efficacy of the proposed lysine restricted diet in confirmed ATQ deficient PDE patients.
II Hypothesis: Restricting dietary lysine intake in infants from age 3 months or less with confirmed diagnosis of
Patients with type 2 diabetes mellitus with and without diabetic nephropathy will be identified from clinical records and approached for their interest in participating in the study. Written informed consent will be obtained from patients who qualify according to the eligibility criteria and agree
All participants will be treated with valproic acid (VPA) at a starting dose of 15 mg/kg/day orally in divided doses. This dose produces a VPA plasma level of 346-693 μM and is the recommended starting dose for patients with seizure disorder. Each week a pre-dose serum VPA level will be determined
Adult subjects with or without diabetes mellitus Eligibility Criteria: undergoing intravenous contrast administration for computerized axial tomography (CAT Scan) as inpatients.
Subjects will be excluded if they have end-stage renal disease (on dialysis or peritoneal dialysis); any known history of
This study is an eight-week, randomized, placebo-controlled, parallel group, fixed dose trial comparing two doses of the alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptor positive modulator, Org 24448, added to a stable dose of atypical antipsychotic medication in 135 patients
Depakote (Abbott Laboratories, Abbott Park, IL) is an anti-convulsant medication used to treat epilepsy [1] and mania associated with bipolar disorder [2, 3]. Depakote also is used as a prophylaxis for migraine headache [4]. One side effect of Depakote that negatively influences its appeal to health